2022 Volume 37 Issue 1 Pages 7-10
The patient is a 66－year－old woman, who has had a melanocytic lesion on her left thigh since she was a high school student. The lesion became elevated in July 2020. The patient was then diagnosed with malignant melanoma, T3bN1aM0, and adjuvant chemotherapy with dabrafenib (300 mg/day) and trametinib (2 mg/day) was started. Two weeks after the start of treatment, the patient complained of foggy vision, prompting ophthalmologic examination. A diagnosis of serous retinal detachment, which was thought to be caused by dabrafenib and trametinib, was made, and the patient chose to discontinue treatment. After 2 weeks of withdrawal, the patient’s foggy vision and retinal detachment findings on fundus examination disappeared, and she resumed medication after a 2－step reduction. Treatment has been continued without recurrence of retinal detachment or progression of the primary disease. Since adverse ocular events can significantly impair the patient’s QOL, it is important to collaborate with ophthalmologists in the treatment of patients.[Skin Cancer (Japan) 2022 ; 37 : 7－10]
